

Q2

	Agreement	Disease Area	Provider included in the gainshare agreement	Name of specific drugs involved	Savings apportioned between CCG and the provider
1	50% Gainshare	N/A	Gloucestershire Hospitals NHS Foundation Trust	All Non Homecare Excluded Drugs	£240k Split £120k CCG £120k Provider (2016/17)
2	Homecare	N/A	Gloucestershire Hospitals NHS Foundation Trust	All Homecare	£65k Split £32.5k CCG £32.5k Provider (2016/17)

Q4

	Agreement	Disease Area	Provider included in the agreement	Name of specific drugs involved	Savings apportioned between CCG and the provider
1	Biosimilar	Rheumatology	Gloucestershire Hospitals NHS Foundation Trust	Infliximab (Inflectra, Remsima, Remicade)	£659k Split £329.5k CCG £329.5k Provider (2016/17)
2	Biosimilar	Rheumatology	Gloucestershire Hospitals NHS Foundation Trust	Etanercept (Benepali, Enbrel)	£135k Split £67.5k CCG £67.5k Provider (2016/17)

Q6

	Agreement	Disease Area	Provider included in the agreement	Name of specific drugs involved	Type of agreement with the Provider
1		Ophthalmology services [eg wet macular degeneration]	Not applicable	Not applicable	Not applicable
2		Multiple Sclerosis	Not applicable	Not applicable	Not applicable
3		Prostate cancer	Not applicable	Not applicable	Not applicable
4		Breast Cancer	Not applicable	Not applicable	Not applicable
5		Haemophilia	Not applicable	Not applicable	Not applicable